Effects Magnesium Sulfate and Labetalol Infusion on Peripheral Perfusion and Pain in Nasal Surgeries

Overview

One of main risk of controlled hypotension during nasal surgeries is impaired perfusion. Peripheral perfusion of non-vital organs usually impaired earlier than vital organs. So, evaluation of perfusion of non-vital organ is considered to be adequate measure of patient safety during surgery. Many hypotensive agents such as dexmedetomidine, B blockers, magnesium sulfate and nitroglycerine had been used but we are in need to investigate its effects on peripheral perfusion. Postoperative pain related to nasal surgeries due to surgical trauma itself which induces the release of inflammatory mediators from neuronal and immune cells resulting in peripheral and central sensitization significantly affects recovery of patients. Magnesium sulfate and labetalol have analgesic actions besides their hypotensive effects but with different mechanisms.

Full Title of Study: “Effects of Magnesium Sulfate and Labetalol Infusion Used for Induced Hypotension on Peripheral Perfusion and Postoperative Pain in Nasal Surgeries”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: September 1, 2021

Detailed Description

To compare between the effects of magnesium sulfate and labetalol infusion during induced hypotension on peripheral perfusion and postoperative pain in nasal surgeries OBJECTIVES: To measure peripheral perfusion index (PPI) as an indicator for peripheral perfusion To calculate the total postoperative rescue analgesic requirements. Double -blind randomized comparative Clinical Study. All Patients will be randomly allocated into two equal groups (group M and Group L). Using computer generated randomization table, each group will be 25 patients.

Interventions

  • Drug: Magnesium Sulfate Injection
    • will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
  • Drug: Labetalol Injectable Solution
    • will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.

Arms, Groups and Cohorts

  • Active Comparator: Magnesium sulfate infudsion
    • patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
  • Active Comparator: Labetalol infusion
    • will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.

Clinical Trial Outcome Measures

Primary Measures

  • Peripheral perfusion index
    • Time Frame: Changes from baseline Peripheral perfusion index at 2 hours.
    • Peripheral perfusion index by pulse oximertry will be measured at basal, 3minutes after induction, every 10 minutes till end of surgery. It will be calculated by dividing the pulsatile signal to nonpulsatile. The normal range is (0.02% -20%)

Secondary Measures

  • Mean arterial blood pressure
    • Time Frame: basal then at 3 minutes after intubation, and after skin incision then every 10 minutes till the end of surgery
    • Mean arterial blood pressure will be recorded at basal, 3 minutes after intubation, and after skin incision then every 10 min till the end of surgery.
  • Heart rate
    • Time Frame: basal then at 3 minutes after intubation, and after skin incision then every 10 minutes till the end of surgery
    • Heart rate will be recorded at basal, 3 minutes after intubation, and after skin incision then every 10 min till the end of surgery.
  • postoperative Pain intensity
    • Time Frame: at 30 minutes, 1 hour, 2hours, 4hours, 6hours, 12hours, and 24hours postoperative.
    • Postoperative Pain will be assessed using Numerical rating Scale (NRS) . A commonly used scale is a 10-cm line labeled with “worst pain imaginable” on the right border and “no pain” on the left border. The patient will be instructed to make a mark along the line to represent the intensity of pain currently being experienced. NRS score 4 or more =pain. Paracetamol 1gm IV will be given every 6 hours as a protocol for pain management will be started at the end of surgery, and IV pethidine 1mg/kg (rescue analgesic) will be given if NRS >4.
  • time to first call for pethidine (rescue analgesic)
    • Time Frame: up to 24hour postoperative
    • Time from the stoppage of infusion solution to first call for pethidine (rescue analgesic) will be recorded.
  • Total pethidine requirements
    • Time Frame: up to 24hour postoperative
    • Total pethidine requirements
  • Serum lactate level
    • Time Frame: basal and at one hour after extubation
    • Serum lactate will be recorded basal and at one hour after extubation. The normal serum lactate ranges from 4.5 to 19.8 mg/dL

Participating in This Clinical Trial

Inclusion Criteria

  • Written informed consent from the patient. – Age: 21-45 years old. – Sex: both sex (males or females). – Physical status: ASA 1& II. – BMI = (20-30 kg/m2). – Type of operations: elective nasal surgeries such as septoplasty, endoscopic sinus surgery and polypectomy. – Duration of surgery ≤ two hours. Exclusion Criteria:

  • Altered mental state – Patients on beta blocker or with known history of allergy to study drugs. – Advanced hepatic, renal, cardiovascular or respiratory diseases. – Diabetic patients. – Patients receiving anticoagulants or on pain killers.

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Zagazig University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Alshaimaa Abdel Fattah Kamel, lecturer of Anesthesia ,and surgical intensive care – Zagazig University
  • Overall Official(s)
    • Alshaimaa Kamel, M.D, Principal Investigator, Faculty of Human medicine, Zagazig university

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.